Impact of current treatment guidelines on minority patients with HIV infection

Valerie Stone1, Luther A Virgil

  • 1Women's HIV/AIDS Services, Massachusetts General Hospital, Boston, Massachusetts, USA.

The AIDS Reader
|October 23, 2004
PubMed

Insights

Updated HIV/AIDS treatment guidelines aim to improve care for adults and adolescents. Their specific benefits for minority patient populations require further investigation to ensure equitable outcomes in human immunodeficiency virus care.

Area of Science:

  • Infectious Diseases
  • Public Health
  • Clinical Medicine

Background:

  • Antiretroviral medicine for HIV/AIDS is complex and rapidly evolving.
  • Clinical research generates substantial data, necessitating frequent guideline updates.
  • The Department of Health and Human Services has issued 11 updates since April 1998.

Purpose of the Study:

  • To analyze the evolution and impact of HIV/AIDS treatment guidelines.
  • To assess the influence of updated antiretroviral therapy recommendations on clinical practice.
  • To investigate the effectiveness of these guidelines in improving outcomes for diverse patient populations, particularly minorities.

Main Methods:

  • Review of updated "Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents."
  • Analysis of guideline dissemination and impact on physician practice.
  • Examination of clinical outcomes data, with a focus on racial and ethnic disparities.

Main Results:

  • Guidelines are frequently updated to reflect advances in antiretroviral therapy.
  • These guidelines influence treatment decisions for a wide range of patients.
  • The impact of these guidelines on improving outcomes in minority HIV patient populations remains unclear.

Conclusions:

  • Continuous updates to HIV/AIDS treatment guidelines are essential.
  • Physician practice is significantly impacted by these evolving recommendations.
  • Further research is needed to confirm the benefits of current HIV/AIDS guidelines for minority populations.

Related Concept Videos

Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Cryptococcal Meningitis01:27

Cryptococcal Meningitis

Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...
Healthcare Associated Infections II: Preventive Measures01:22

Healthcare Associated Infections II: Preventive Measures

Essential infection prevention measures are based on the knowledge of the infection chain, the modes of transmission in healthcare settings, and the use of the best practices in all healthcare settings. Compulsory public reporting of healthcare-associated infection rates is needed to allow individuals and the community to make informed choices regarding selecting a healthcare facility.
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...